ES2065933T3 - Metodo de analisis mutacional rapido. - Google Patents

Metodo de analisis mutacional rapido.

Info

Publication number
ES2065933T3
ES2065933T3 ES89106627T ES89106627T ES2065933T3 ES 2065933 T3 ES2065933 T3 ES 2065933T3 ES 89106627 T ES89106627 T ES 89106627T ES 89106627 T ES89106627 T ES 89106627T ES 2065933 T3 ES2065933 T3 ES 2065933T3
Authority
ES
Spain
Prior art keywords
quick
analysis method
mutational analysis
antibodies
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89106627T
Other languages
English (en)
Inventor
Brian Seed
Andrew Peterson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Application granted granted Critical
Publication of ES2065933T3 publication Critical patent/ES2065933T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • AIDS & HIV (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)

Abstract

UN METODO DE ANALISIS MUTACIONAL RAPIDO PARA APLICACIONES EPITOPES DE PROTEINA ES DESCUBIERTO. ESTE METODO HA SIDO USADO PARA IDENTIFICAR LOS SITIOS DE ATADURA PARA 16 ANTICUERPOS MONOCLONADOS ANTI-CD2 Y ANTI-CD4. EL PODEROSO, RAPIDO Y SIMPLE METODO DEL PRESENTE INVENTO PERMITE AISLAR UN MUY GRAN NUMERO DE MUTANTES Y ES APLICABLE A CUALQUIER PROTEINA DE SUPERFICIE POR EL QUE CUN CDNA Y ANTICUERPOS MONOCLANALES SON DISPONIBLES. EL PRESENTE METODO ES ESPECIALMENTE UTIL EN EL SITIO DE ATAR LIGANDO ESTUCHADOS PARA EL DISEÑO DE NUEVOS LIGANDOS Y MEDICAMENTOS.
ES89106627T 1988-04-15 1989-04-13 Metodo de analisis mutacional rapido. Expired - Lifetime ES2065933T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18182688A 1988-04-15 1988-04-15

Publications (1)

Publication Number Publication Date
ES2065933T3 true ES2065933T3 (es) 1995-03-01

Family

ID=22665974

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89106627T Expired - Lifetime ES2065933T3 (es) 1988-04-15 1989-04-13 Metodo de analisis mutacional rapido.

Country Status (8)

Country Link
US (3) US5411861A (es)
EP (1) EP0341444B1 (es)
JP (1) JPH02203787A (es)
AT (1) ATE114821T1 (es)
DE (1) DE68919524T2 (es)
DK (1) DK172110B1 (es)
ES (1) ES2065933T3 (es)
PT (1) PT90265B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK172110B1 (da) 1988-04-15 1997-10-27 Gen Hospital Corp Fremgangsmåde til isolation af mutanter af DNA-sekvenser og anvendelsen heraf til identifikation af celleoverfladeproteiner
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
KR927003613A (ko) * 1989-08-23 1992-12-18 더 제너랄 호스피탈 코오퍼레이숀 비-인체 영장동물의 cd4폴리텝타이드, 글리코실화할 수 있는 인체 cd4분자, 그것의 단편, 그것의 융합 단백질, 유전자 서열 및 그것의 용도
US7413537B2 (en) 1989-09-01 2008-08-19 Dyax Corp. Directed evolution of disulfide-bonded micro-proteins
JPH0725794B2 (ja) * 1990-03-23 1995-03-22 呉羽化学工業株式会社 新規なペプチド
EP1820858B1 (en) 1991-03-01 2009-08-12 Dyax Corporation Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
GB9114734D0 (en) * 1991-07-09 1991-08-28 Univ London Process for modifying proteins
US5648220A (en) * 1995-02-14 1997-07-15 New England Medical Center Hospitals, Inc. Methods for labeling intracytoplasmic molecules
US6576465B1 (en) * 1997-11-10 2003-06-10 The Regents Of The University Of Michigan Human bone accessory cells
US6689566B1 (en) 1999-01-14 2004-02-10 Scantibodies Laboratory, Inc. Methods, kits, and antibodies for detecting parathyroid hormone
US7820393B2 (en) * 1999-01-14 2010-10-26 Scantibodies Laboratory, Inc. Methods, kits and antibodies for detecting parathyroid hormone
US20030186311A1 (en) * 1999-05-21 2003-10-02 Bioforce Nanosciences, Inc. Parallel analysis of molecular interactions
US20030228687A1 (en) * 2000-08-07 2003-12-11 The Regents Of The University Of Michigan Human bone accessory cells
DE10256042B4 (de) * 2002-11-30 2006-06-08 Universität Potsdam Verfahren zur Selektion von Zellen, die spezifisch bindende Moleküle produzieren
KR100540659B1 (ko) * 2003-07-02 2006-01-10 삼성전자주식회사 이미지 확대 인쇄 방법과 장치 및 컴퓨터 프로그램을저장하는 컴퓨터로 읽을 수 있는 기록 매체
US20050202506A1 (en) * 2004-03-11 2005-09-15 Cantor Thomas L. Methods for identifying and producing specific amino acid dependent antibodies and uses thereof
AU2007200847B2 (en) * 2004-07-27 2010-06-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes and methods for their use
CA2576798C (en) 2004-07-27 2014-09-09 Gwong-Jen J. Chang Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes and methods for their use
US11421028B2 (en) 2016-02-06 2022-08-23 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
EP3788079A4 (en) 2018-05-03 2022-12-21 Shanghai Epimab Biotherapeutics Co., Ltd. ANTIBODIES WITH HIGH AFFINITY TO PD-1 AND LAG-3 AND BI-SPECIFIC BINDING PROTEINS PRODUCTION THEREOF

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361550A (en) * 1979-12-04 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human suppressor T cells and methods of preparing same
EP0095502A4 (en) * 1981-12-08 1987-01-20 Univ South Carolina MONOCLONIC HUMAN ANTIBODIES OR LYMPHOCINS IN CELL SEPARATION OR IN DIAGNOSIS OF BREAST CANCER.
US4677056A (en) * 1983-08-18 1987-06-30 Sloan-Kettering Institute For Cancer Research Monoclonal antibody subsetting human helper and killer T-cells and method
US4772552A (en) * 1984-04-23 1988-09-20 Dana-Farber Cancer Institute, Inc. Monoclonal antibody which recognizes a 200-220 KD antigen on natural killer cells
US4675285A (en) * 1984-09-19 1987-06-23 Genetics Institute, Inc. Method for identification and isolation of DNA encoding a desired protein
US4677061A (en) * 1984-10-19 1987-06-30 Genetic Systems Corporation T-cell lymphocyte subset monitoring of immunologic disease
US4818679A (en) * 1985-02-19 1989-04-04 The Trustees Of Columbia University In The City Of New York Method for recovering mutant cells
DK172110B1 (da) 1988-04-15 1997-10-27 Gen Hospital Corp Fremgangsmåde til isolation af mutanter af DNA-sekvenser og anvendelsen heraf til identifikation af celleoverfladeproteiner

Also Published As

Publication number Publication date
EP0341444A2 (en) 1989-11-15
EP0341444A3 (en) 1990-11-14
US6579676B1 (en) 2003-06-17
DK172110B1 (da) 1997-10-27
DE68919524D1 (de) 1995-01-12
ATE114821T1 (de) 1994-12-15
DK172589A (da) 1989-12-12
PT90265B (pt) 1994-07-29
US5411861A (en) 1995-05-02
DK172589D0 (da) 1989-04-11
DE68919524T2 (de) 1995-05-04
PT90265A (pt) 1989-11-10
JPH02203787A (ja) 1990-08-13
EP0341444B1 (en) 1994-11-30
US5955264A (en) 1999-09-21

Similar Documents

Publication Publication Date Title
ES2065933T3 (es) Metodo de analisis mutacional rapido.
DK0616613T3 (da) Fragmenter af prionprotein
NO944207L (no) Farmasöytiske og andre doseringsformer
ES2146212T3 (es) Proteinas de union a antigenos trivalentes monoespecificas.
ES2132601T3 (es) Procedimiento para la seleccion de bacteriofagos especificos.
ES2136654T3 (es) Herramientas para el diagnostico y tratamiento de la enfermedad de alzheimer.
DE69112717D1 (de) Neue Verwendung von Modafinil.
ES2062706T3 (es) Nuevos derivados de amino-metil-piperidina su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
MX24890A (es) Polipeptido sintetico, procedimiento par su preparacion y composicion farmaceutica que lo contiene.
GR1001407B (el) Υποκατεστημένες ισοξαζολιδίνες και ισοξαζολίνες.
DE3751316D1 (de) Materialzusammensetzung, welche ein Polypeptid aus Pankreas-Insel-Amyloid und/oder Antikörpern gegen dieses Polypeptid enthält, und Anwendung dieser Zusammensetzung.
MX9301675A (es) Composiciones que contienen peptidos para inducir tolerancia de las celulas t a un antigeno.
ES2074591T3 (es) Expresion de polipeptidos de vih 1 y 2 y su utilizacion.
PT92503A (pt) Processo para a preparacao de novos derivados peptidicos com accao anti-coagulante
ES2082017T3 (es) Anticuerpo monoclonal que reconoce el epitopo especifico de glucosidos de antraciclina e hibridoma que secreta dicho anticuerpo.
Wifall The Chronology of the divided monarchy of Israel
DK214087A (da) Compleximmunogen
ES2066739B1 (es) Inmunoensayo para analitos en muestras empleando agentes alquilantes.
ATE184315T1 (de) Neuartiges endothelzell-molekül, das die bindung von lymphozyten im menschen vermittelt
FR1216001A (fr) Liant anhydrite fabriqué à partir de l'anhydrite naturelle
GB1064929A (en) 1,1-diphenyl-1-methoxy-3-benzyl amino propane and salts thereof and a process for the preparation thereof
CH895A (fr) Boîte de montre, servant en même temps d'album photographique
Lyon Jr A Peculiar Mutation of the Pine Marten
Arndt The First Wabash Song
ES2059726T3 (es) Anticuerpos monoclonales que reconocen el itsp humano, hibridomas que producen los mismos, y su preparacion y uso.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 341444

Country of ref document: ES